Company profile
Veracyte, Inc.
NASDAQ: VCYT · Healthcare · Medical - Diagnostics & Research
#207 of 1,418 Healthcare companies by revenue62nd-percentile growth
EA Score
82B+FH 91DQ 79GM 66SS 78
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, revenue growth (YoY)
Methodology →Revenue TTM
$541.7M
Rev growth YoY (TTM)
+16.9%
Net income (FY)
$66.4M
Employees
755
as of 2026-08-07
Market cap
$3.7B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$517.1M$517.1M2025
Net income$66.4M$66.4M2025
Operating income$57.8M$57.8M2025
Total assets$1.4B$1.4B2025
Liabilities$96.4M$96.4M2025
Equity$1.3B$1.3B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Testing95%
Product3%
Biopharmaceutical And Other2%
By geography
UNITED STATES96%
Non-US4%
The read
What is Veracyte, Inc.’s revenue?
Veracyte, Inc. booked $517.1M in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a 12.8% net margin.
Peers · Healthcare
Organogenesis Holdings Inc.65BAtriCure, Inc.84B+Mirum Pharmaceuticals, Inc.64CInotiv, Inc.63CADMA Biologics, Inc.85AGlaukos Corporation71BNeighbors
San Mateo →Key facts
CEOMarc Stapley
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: VCYT
Employees755
IPO date2013-10-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.